Seeking Alpha

The FDA has approved GlaxoSmithKline's (GSK) Tafinlar and Mekinist drugs for treating melanoma...

The FDA has approved GlaxoSmithKline's (GSK) Tafinlar and Mekinist drugs for treating melanoma that has spread or can't be surgically removed. The drugs, which are aimed at patients with certain gene mutations, are expected to generate annual sales of $622M by 2016, and will compete with Roche's (RHHBY.OB) Zelboraf and Bristol-Myers Squibb's (BMY) Yervoy. GSK's shares -0.4% in London. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs